Get the Stockscreener App
9.27
2.63%
-0.25
After Hours:
9.32
0.05
+0.54%
Anavex Life Sciences Corporation stock is traded at $9.27, with a volume of 3.56M.
It is down -2.63% in the last 24 hours and up +4.45% over the past month.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
See More
Previous Close:
$9.52
Open:
$9.44
24h Volume:
3.56M
Relative Volume:
3.16
Market Cap:
$796.24M
Revenue:
-
Net Income/Loss:
$-48.17M
P/E Ratio:
-16.26
EPS:
-0.57
Net Cash Flow:
$-37.10M
1W Performance:
-6.93%
1M Performance:
+4.45%
6M Performance:
+8.55%
1Y Performance:
+81.41%
1-Day Range:
$9.00
$9.525
1-Week Range:
$9.00
$10.38
52-Week Range:
$5.11
$14.44
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
Name
Anavex Life Sciences Corporation
Sector
Industry
Phone
844-689-3939
Address
630 5TH AVENUE, NEW YORK
Compare AVXL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
9.27 | 817.71M | 0 | -48.17M | -37.10M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Sep-23-21 | Initiated | BTIG Research | Buy |
| Dec-16-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-28-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-27-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-18-19 | Initiated | Janney | Buy |
| May-16-18 | Resumed | Maxim Group | Buy |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Feb-07-17 | Initiated | Noble Financial | Buy |
| Mar-29-16 | Initiated | FBR Capital | Outperform |
View All
Anavex Life Sciences Corporation Stock (AVXL) Latest News
Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’ - The Manila Times
Anavex Life Sciences Corp. Announces Oral Presentation on Alzheimer's Disease Care at Alzheimer Europe Conference - Quiver Quantitative
Oral Blarcamesine Presented at 35th Alzheimer Europe — Anavex Highlights ANAVEX®2-73-AD-004 IIb/III - Stock Titan
Will Anavex Life Sciences Corp. (12X1) stock keep high P E multiplesJuly 2025 Analyst Calls & Growth Focused Investment Plans - newser.com
Is Anavex Life Sciences Corp. (12X1) stock testing key supportWeekly Trade Report & Community Verified Trade Alerts - newser.com
Anavex Life Sciences (NASDAQ:AVXL) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Anavex Life Sciences (NASDAQ:AVXL) Receives Buy Rating from HC Wainwright - MarketBeat
HC Wainwright & Co. Reiterates Anavex Life Sciences (AVXL) Buy Recommendation - Nasdaq
Anavex Life Sciences stock rating reiterated at Buy by H.C. Wainwright - Investing.com
How Anavex Life Sciences Corp. stock reacts to global recession fearsBreakout Watch & Low Drawdown Momentum Ideas - newser.com
Long term hold vs stop loss in Anavex Life Sciences Corp.Analyst Downgrade & Community Consensus Stock Picks - newser.com
Tools to monitor Anavex Life Sciences Corp. recovery probabilityEarnings Risk Report & Advanced Technical Signal Analysis - newser.com
Anavex Life Sciences (NASDAQ:AVXL) Trading Up 8.7%Should You Buy? - MarketBeat
Anavex Life Sciences (Nasdaq:AVXL) Reports Positive Phase 2 Results for ANAVEX®3-71 in Schizophrenia - Kalkine Media
D. Boral Capital Maintains Anavex Life Sciences (AVXL) Buy Recommendation - Nasdaq
Is Anavex Life Sciences Corp a good long term investmentBollinger Bands Signals & Free Phenomenal Capital Appreciation - earlytimes.in
Anavex: ANAVEX 3-71 Could Potentially Offer Disease-Modifying Effects For Schizophrenia - Seeking Alpha
Anavex Life Sciences (NASDAQ:AVXL) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Anavex Life Sciences (AVXL): Analyst Reaffirms "Buy" Rating | AV - GuruFocus
Anavex Life Sciences Stock Just Shot Up 7% Today – Here’s An Important Update - Stocktwits
Anavex Life Sciences (AVXL) Shares Rise on Positive Trial Result - GuruFocus
Anavex Life Sciences Reports Positive Phase 2 Results for ANAVEX®3-71 in Schizophrenia Clinical Study Achieving Safety and Tolerability Endpoints - Quiver Quantitative
Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program - The Manila Times
Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia - The Manila Times
Anavex Life Sciences stock rises after positive schizophrenia drug trial - Investing.com
Anavex Develops Once-Daily Tablet for ANAVEX3-71 in Phase 1b Trial | AVXL Stock News - Stock Titan
Novel Schizophrenia Drug ANAVEX3-71 Shows Promise: Safe Profile and Reduced Brain Inflammation Markers - Stock Titan
Anavex Life Sciences (NASDAQ:AVXL) Receives “Buy” Rating from D. Boral Capital - Defense World
Alzheimer’s Disease Market: Epidemiology, Therapies, and Key Players | Anavex Life Sciences Corp., TauRx Therapeutics Ltd, BioVie Inc., AriBio Co., Ltd., Novo Nordisk A/S, AgeneBio, Neurim Pharmaceuti - Barchart.com
Anavex Life Sciences (NASDAQ:AVXL) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Alzheimer's Disease Market: Epidemiology, Therapies, And Key Players Anavex Life Sciences Corp., Taurx Therapeutics Ltd, Biovie Inc., Aribio Co., Ltd., Novo Nordisk A/S, Agenebio, Neurim Pharmaceuti - Menafn.com
Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial - markets.businessinsider.com
Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer's Disease Trial - Investing News Network
Anavex Life Sciences Announces Publication of Oral - GlobeNewswire
70% Success Rate: Anavex's Once-Daily Oral Alzheimer's Drug Shows Breakthrough Results in Late-Stage Trial - Stock Titan
Why millennials buy Anavex Life Sciences Corp. (12X1) stockJuly 2025 PostEarnings & Daily Price Action Insights - newser.com
How Anavex Life Sciences Corp. stock valuations compare to rivalsJuly 2025 Selloffs & Verified Momentum Stock Ideas - newser.com
How to recover losses in Anavex Life Sciences Corp. stockJuly 2025 Drop Watch & Safe Entry Point Identification - newser.com
Real time pattern detection on Anavex Life Sciences Corp. stockMarket Volume Summary & Target Return Focused Stock Picks - newser.com
What drives PRCT stock priceMarket Sentiment Shifts & These 3 Stocks Could Change Your Portfolio - earlytimes.in
What drives Anavex Life Sciences Corp stock priceOptions Trading Strategies & Minimal Capital Growth Plans - earlytimes.in
What analysts say about Anavex Life Sciences Corp stockEquity Performance Review & Stocks With 200% Upside Potential - Early Times
How Anavex Life Sciences Corp. (12X1) stock trades pre earningsJuly 2025 Gainers & Free Safe Entry Trade Signal Reports - newser.com
H.C. Wainwright Reiterates Its ‘Buy’ Rating on Anavex Life Sciences Corp. (AVXL) with a $42 Price Target - Insider Monkey
Anavex Life Sciences Corp. $AVXL Shares Sold by Goldman Sachs Group Inc. - MarketBeat
Published on: 2025-09-22 05:58:42 - newser.com
Aug Drivers: Can Anavex Life Sciences Corp weather a recessionSwing Trade & Low Risk Entry Point Guides - خودرو بانک
Aug Technicals: What is the PEG ratio of Anavex Life Sciences CorpJuly 2025 Intraday Action & Accurate Entry and Exit Point Alerts - خودرو بانک
Should I hold or sell Anavex Life Sciences Corp now2025 EndofYear Setup & Accurate Intraday Trade Tips - خودرو بانک
What momentum shifts mean for Anavex Life Sciences Corp.Inflation Watch & Technical Pattern Alert System - newser.com
Short interest data insights for Anavex Life Sciences Corp.2025 Growth vs Value & Scalable Portfolio Growth Methods - newser.com
Anavex Life Sciences Corporation Stock (AVXL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anavex Life Sciences Corporation Stock (AVXL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thomas Steffen | Director |
Jun 05 '25 |
Option Exercise |
1.76 |
50,000 |
88,000 |
55,000 |
| MISSLING CHRISTOPHER U | President and CEO |
Mar 24 '25 |
Option Exercise |
0.92 |
500,000 |
460,000 |
1,750,210 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):